

Submitted by: Chief Medical Officer  
Name: Johnathan Lancaster, MD, PhD  
Company/Organization: Myriad Genetic Laboratories, Inc.  
Address: 320 Wakara Way, Salt Lake City, UT 84108  
Phone: 801-505-5090  
Email: [jlancaster@myriad.com](mailto:jlancaster@myriad.com)  
Date of request: August 17, 2016  
NCCN Guidelines Panel: Gastric Cancer

Specific Changes: Expand the "Criteria for Further Risk Evaluation for High-Risk Syndromes" on page GAST-D1 to include syndromes other than Hereditary Diffuse Gastric Cancer (HDGC) by adding bullet points for patients with:

- Gastric cancer and a personal or family history of cancers associated with Lynch syndrome (colorectal, endometrial, small bowel, or urinary tract).
- Gastric cancer and a personal or family history of gastrointestinal polyposis including adenomatous, juvenile or other types of polyps

FDA Clearance: Not applicable.

Rationale: The current risk evaluation criteria on page GAST-D1 appear to be focused almost exclusively on HDGC, without accounting for the association of gastric cancer with the extensive list of additional hereditary cancer syndromes described subsequently on pages GAST-D2 to GAST-D6.

Citations:

Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal. V 1.2016. June 13. Available at <http://www.nccn.org>.

Sincerely,

A handwritten signature in black ink, appearing to be 'J. Lancaster', written over a circular stamp or seal.

Johnathan Lancaster, MD, PhD  
Chief Medical Officer, Myriad Genetic Laboratories Inc.